Mirae Asset Global Investments Co. Ltd. Acquires 872 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,809 shares of the specialty pharmaceutical company’s stock after acquiring an additional 872 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Supernus Pharmaceuticals were worth $689,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its stake in Supernus Pharmaceuticals by 96.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock worth $39,000 after acquiring an additional 687 shares during the last quarter. Covestor Ltd increased its stake in Supernus Pharmaceuticals by 115.0% in the 3rd quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 1,257 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth about $262,000. Profund Advisors LLC increased its stake in Supernus Pharmaceuticals by 17.7% in the 3rd quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 1,454 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Supernus Pharmaceuticals by 28.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company’s stock worth $274,000 after purchasing an additional 2,203 shares in the last quarter.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $30.21, for a total transaction of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $258,899.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $30.21, for a total transaction of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $258,899.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total value of $436,572.84. Following the sale, the vice president now owns 8,570 shares of the company’s stock, valued at $302,606.70. The disclosure for this sale can be found here. Insiders sold 35,739 shares of company stock worth $1,227,433 in the last ninety days. 8.76% of the stock is owned by company insiders.

Supernus Pharmaceuticals Trading Up 1.0 %

SUPN opened at $30.26 on Thursday. The stock has a 50-day moving average price of $31.47 and a 200-day moving average price of $28.59. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $38.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The firm had revenue of $164.30 million during the quarter, compared to analysts’ expectations of $155.03 million. Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. Supernus Pharmaceuticals’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 earnings per share. On average, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Piper Sandler cut their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.